Priya Hays

American molecular biologist (born 1968)

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023)

|

Priya Venkatesan Hays

Born|  (1968-09-22) September 22, 1968 (age 55)
Nationality| American
Education|

* B.A. – Dartmouth College
* Master's degree in Genetics – University of California, Davis
* Ph.D. in Literature – University of California, San Diego

Known for| Research in cancer, molecular biology and personalized medicine
Scientific career
Fields| molecular biology
Institutions|

* Dartmouth College
* University of California, Davis
* University of California, San Diego
* Santa Clara University
* San Francisco State University

Website| Main publications

Priya Venkatesan Hays (born September 22, 1968) is an American scientist focusing on cancer, molecular biology and personalized medicine.[1] She was elected to medical societies Allied Physician/Doctoral Scientist of the American Society of Clinical Oncology; as an Affiliate Member of the American College of Medical Genetics and Genomics; and as a Member of the Society for Immunotherapy of Cancer.[2] She is also a member of the Silicon Valley chapter of the Society for Technical Communication.

## Education[edit]

Hays holds a B.A (Bachelor of Arts) degree from Dartmouth College.[3] She furthered her education by obtaining a Master's degree in Genetics from the University of California, Davis and a Ph.D. in Literature from the University of California, San Diego.[4]

## Career[edit]

Following her formal education, Hays conducted research during a postdoctoral fellowship at Dartmouth Medical School.[5] Subsequently, she transitioned to teaching roles, where she taught science writing at Santa Clara University[6] and San Francisco State University.[7]

She has authored five books (for one she served as editor on cancer immunotherapies) and written 16 articles for academic journals. Additionally, she has delivered presentations at 30 conferences, both nationally and internationally.[8]

## Research[edit]

Hays' research interests are primarily focused on biomedicine.[9] She also studies precision oncology,[1] personalized medicine[10][8], cancer immunotherapies biomedicine.[10][11][12]

In addition to her biomedicine research, Hays has an active interest in science and technology policy. She concentrates on policy areas related to biomedical and nanotechnology.[13]

She wrote and published the Second Edition of Advanced Healthcare Through Personalized Medicine in 2022, which The ASCO Post described as the “depth of technical information and wellspring of novel advances carefully woven into a personalized medicine[8] matrix are admirable” and “a top-notch operation from cover to cover”.[14]

Doody’s Medical Review referred to the Second Edition as “an extraordinary compendium of the state of the art in personalized medicine, bringing together some of the important research that is building the foundation for future standards of medical care,” [15] The reviews discusses Dr. Hay’s comprehensive book on personalized medicine, highlighting her credentials as a science writer and her affiliation with prestigious medical organizations.[14][15]

## Bibliography[edit]

### Journals[edit]

* Hays, Priya Venkatesan (1 September 2013). "Epistemic Cross Talk". Interdisciplinary Literary Studies. 15 (2): 221–239. doi:10.5325/intelitestud.15.2.0221. S2CID 141018401. [16]
* Hays, Priya (July 2020). "Clinical sequelae of the novel coronavirus: does COVID-19 infection predispose patients to cancer?". Future Oncology (London, England). 16 (20): 1463–1474. doi:10.2217/fon-2020-0300. PMC 7255429. PMID 32456461. [16]
* Hays, Priya (2022). "Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies". Cancer Immunotherapies. Cancer Treatment and Research. 183: 287–315. doi:10.1007/978-3-030-96376-7_11. ISBN 978-3-030-96375-0. PMID 35551665. [16]
* Hays, Priya; Costello, Caitlin; Asudani, Deepak (December 2019). "Clinical care of chimeric antigen receptor T-cell patients and managing immune-related adverse effects in the ambulatory and hospitalized setting: a review". Future Oncology. 15 (36): 4235–4246. doi:10.2217/fon-2019-0467. PMID 31773980. S2CID 208322232. [16]
* Hays, Priya (July 2019). "Personalized medicine: paradigm shift or revolution". Genetics in Medicine. 21 (7): 1662. doi:10.1038/s41436-018-0379-8. PMID 30467405. S2CID 256624543. [16][17]
* Hays, Priya (February 2022). "Tumor Agnostic Models for NSCLC Drug Development". International Journal of Radiation Oncology*Biology*Physics. 112 (2): e19. doi:10.1016/j.ijrobp.2021.10.197. [16]

### Books[edit]

* Venkatesan Hays, Priya (2006). Molecular biology in narrative form: a study of the experimental trajectory of science. New York: P. Lang. ISBN 978-0820486994.
* Venkatesan Hays, Priya (2017). Advancing Healthcare Through Personalized Medicine (2nd ed.). CRC Press. p. 184\. ISBN 978-1498767088.
* Hays, Priya (2021) Advancing Healthcare Through Personalized Medicine (2nd edition), Springer, ISBN 978-3030800994

## References[edit]

1. ^ a b "Dr Priya Hays, PhD, considers how the rapid development of precision medicine for oncology has impacted diagnosis, treatment, and clinical outcomes in cancer care". Open Access Government.
2. ^ Piana, Ronald. "A Second Edition Adds New Value to Personalized Medicine - The ASCO Post". ascopost.com.
3. ^ Harris, Samantha (12 June 2008). "'If You Can't Teach 'Em, Sue 'Em' | The Foundation for Individual Rights and Expression". www.thefire.org.
4. ^ Berk, Jamie. "The Dartmouth Independent: A Postmodernist in the Laboratory...and Courtroom?". Dartmouth independent.
5. ^ Vinod (8 May 2008). "The Strange, Twisted Tale of Priya Venkatesan, PhD | Sepia Mutiny". Sepia Mutiny.
6. ^ Barlett, Tom. "Dear professor anonymous". The Chronicle of Higher Education.
7. ^ Rosenthal, Brian (15 May 2008). "Venkatesan trying to move on at NU". The Daily Northwestern.
8. ^ a b c Hays, Priya (July 2019). "Personalized medicine: paradigm shift or revolution". Genetics in Medicine: Official Journal of the American College of Medical Genetics. 21 (7): 1662. doi:10.1038/s41436-018-0379-8. ISSN 1530-0366. PMID 30467405.
9. ^ "walsh medical media | journals | open access journals". www.walshmedicalmedia.com. 25 November 2019.
10. ^ a b Science writer Dr Priya Hays covers these in the second edition of her book Advancing Healthcare Through Personalized Medicine https://researchfeatures.com/wp-content/uploads/2022/12/Priya-Hays.pdf
11. ^ https://link.springer.com/book/10.1007/978-3-030-96376-7
12. ^ https://www.gimjournal.org/article/S1098-3600(22)00192-7/fulltext
13. ^ 2244035653574/Hays-Priya/Advancing-Healthcare-Through-Personalized-Medicine "Advancing Healthcare Through Personalized Medicine Hays, Priya". morawa.at (in Austrian German). `{{cite web}}`: Check `|url=` value (help)
14. ^ a b May 25, Ronald Piana; 2022. "A Second Edition Adds New Value to Personalized Medicine - The ASCO Post". ascopost.com. Retrieved 2023-11-01.`{{cite web}}`: CS1 maint: numeric names: authors list (link)
15. ^ a b "Doody's Review Service - Welcome". www.doody.com. Retrieved 2023-11-01.
16. ^ a b c d e f "Hays P - Search Results - PubMed". PubMed. Retrieved 2023-11-01.
17. ^ Hays, Priya (July 2019). "Personalized medicine: paradigm shift or revolution". Genetics in Medicine. 21 (7): 1662–1662. doi:10.1038/s41436-018-0379-8. ISSN 1530-0366.

## External links[edit]

* Main publications
* Priya Hays publications indexed by Google Scholar
* Second Edition Adds New Value to Personalized Medicine